Drug GMP “Surveillance” Will Link Compliance Information To Inspections
This article was originally published in The Tan Sheet
Executive Summary
CDER Director Janet Woodcock says a new database will drive risk-based inspection decisions. Once active and combined with new objective quality measurement data, the system should allow all relevant agency personnel access to the same information in the hopes of improving oversight.
You may also be interested in...
FDA To Update Quality Metrics Guidance
It's the only addition to the agency's 2016 agenda.
FDA To Update Quality Metrics Guidance
It's the only addition to the agency's 2016 agenda.
FDA Could Release GMP Data To Prod Manufacturing Improvements
Batch failure and other measures commonly tracked by manufacturers could be aggregated into an industry-wide index that FDA would use to help make risk-based inspection decisions.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: